Actinogen CEO explains Xanamem Alzheimer’s trial; eyes November milestone

Actinogen Medical CEO Dr Steven Gourlay talked with Proactive about the company’s approach to targeting elevated brain cortisol with its investigational drug Xanamem, and the upcoming clinical trial readout assessing its potential to slow functional and cognitive decline in Alzheimer’s disease. The company's current study involves 247 patients and is designed to assess whether Xanamem can significantly slow functional and cognitive decline compared with placebo. Results are expected in November. He also outlined the potential next steps if results are positive, including discussions with regulators about expedited development pathways, preparation for a larger pivotal study and potential partnerships with larger pharmaceutical companies to support development and commercialisation. Visit Proactive’s YouTube channel for more interviews and market updates. Don’t forget to give the video a like, subscribe to the channel and enable notifications for future content.